当飞利肝宁联合苦参素抗肝纤维化的临床观察.pdfVIP

当飞利肝宁联合苦参素抗肝纤维化的临床观察 右江民族医学院附属医院感染疾病科 覃后继 何延专 周耀南 陆春雷 （533000） 摘要：目的 观察当飞利肝宁联合苦参素治疗乙肝病毒感染的不同肝病患者肝纤维化的价值。方法 采用RIA 法，分别检 测123 例不同肝病患者当飞利肝宁联合苦参素治疗前和治疗6 个月后血清肝纤维化指标（LN、HA、PCⅢ、CⅣ），另31 例慢乙肝采用单一苦参素治疗，用同法检测其血清含量。结果 LN、HA、PCⅢ、CⅣ在不同组别下降幅度不一，乙肝病 毒携带者组t 值分别为2.19、2.40、2.25、2.88，慢乙肝组为3.77、3.18、3.71、4.81，代偿期肝硬化组为2.53、4.26、 3.97、2.52 （P 均0.1）,失代偿肝硬化组为0.27、0.42、0.55、0.52 （P0.1）。单一苦参素治疗慢性乙肝组，抗肝纤 维化能力小于联合用药组。结论 1、联合治疗可使乙肝病毒携带者，慢性乙肝，代偿期肝硬化患者血清LN、HA、PCⅢ、 CⅣ含量显著下降。失代偿期肝硬化组血清LN、HA、PCⅢ、CⅣ含量无明显变化，但能阻止或延缓病变进程。2、当飞利 肝宁联合苦参素抗慢乙肝纤维化疗效明显优于单用苦参素。 关键词：肝纤维化；当飞利肝宁；苦参素； Clinical obseration of the effect of the Dangfeiliganning+Marine combination on anti-hepatic fibrosis Hou-Ji Qin, Yan-Zhuan He,Yiao-Nan Zhou, Chun-Lei Lu Affiliated Hospital of Youjiang Medical College for Nationalities,Baise,Guangxi,P.R.Chine 533000. [Abstract] Objective We observed the value of the Dangfeiliganning+Marine combination in the treatment of hepatic fibrosis resulting from hepatitis B virus. Methods The concentration of serum LN,HA,PCⅢ,CⅣ in 123 viral B hepatitis patients treated with the Dangfeiliganning+Marine combination and in 31 chronic viral B hepatitis patients treated with the Marine alone were measured by radioimmunoassay before and after 6 months therapy. Results In the treatment of the Dangfeiliganning+Marine combination patients, the levels of serum LN,HA,PCⅢ,CⅣ(t value) were all decreased in different groups. The HBsAg carrier group were 2.19,2.40,2.25,2.88(P0.1).The chronic hepatitis B group were 3.77,3.18,3.71,4.81(P0.1),whose anti-hepatic fibrosis was more effective than the same group treated with the Marine alone. The compensated liver cirrhosis group were 2.53,4.26,3.97,2.52(P0.1). The decompensated liver cirrhosis group were 0.27,0.42,0.55,0.52(P0.1). Conclusion The treatment of the Dangfeiliganning+Marine combination make the levels of serum LN,HA,PCⅢ,C Ⅳ in the HBsAg car